ABL1 and acute lymphoblastic leukemia: In Ph-positive ALL, ABL kinase mutations mainly include E255v, T315I, Y253, etc. T315I mutation has the highest frequency among these and is associated with rapid disease progression and worse prognosis16,17, and it is resistant to TKI drugs such as Imatinib dasatinib, but the third-generation TKI such as ponatinib, olverembatinib [a4] can overcome this mutation18.